中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2012年
3期
253-255
,共3页
屈蕾蕾%张衡中%刘丽君%达春和
屈蕾蕾%張衡中%劉麗君%達春和
굴뢰뢰%장형중%류려군%체춘화
恶性胸膜间皮瘤%培美曲塞%顺铂%卡铂%化学治疗
噁性胸膜間皮瘤%培美麯塞%順鉑%卡鉑%化學治療
악성흉막간피류%배미곡새%순박%잡박%화학치료
Malignant pleural mesothelioma%Pemetrexed%Cisplatin%Carboplatin%Chemotherapy
目的 探讨恶性胸膜间皮瘤两种内科保守治疗方案培美曲塞联合顺铂与培美曲塞联合卡铂的治疗生存率是否存在差异.方法 我院2005 - 2009年经病理学确诊为恶性胸膜间皮瘤患者17例,临床分期达到Butchart标准Ⅲ期及以上者,分别采用培美曲塞联合顺铂(10例)与培美曲塞联合卡铂(7例)两种方案化疗,对患者的生存率进行统计,了解是否存在差异.结果 培美曲塞联合顺铂组患者,早期生存率(1～3个月)略高于培美曲塞联合卡铂组患者,但其差异并无统计学意义(x2值分别为0、1.52、1.52,P均＞0.05).中期(4～9个月)生存率培美曲塞联合顺铂组高于培美曲塞联合卡铂组,差异有统计学意义(x2值分别为5.21、4.41、4.41、4.50、4.50、4.55,P均＜0.05).中远期生存率(10～ 12个月),培美曲塞联合顺铂组与培美曲塞联合卡铂组生存曲线趋向一致,差异并无统计学意义(x2值分别为1.31、0.09、0.09,P均＞0.05).结论 为增加中期生存率,应尽力采用培美曲塞联合顺铂方案.对于部分副反应较大,采用维生素B12及叶酸等辅助药物能够缓解的患者亦应选择此方案.但对于采用了上述方式后仍不能降低副作用者选择培美曲塞联合卡铂的方法也是适当的,尤其是身体虚弱者.
目的 探討噁性胸膜間皮瘤兩種內科保守治療方案培美麯塞聯閤順鉑與培美麯塞聯閤卡鉑的治療生存率是否存在差異.方法 我院2005 - 2009年經病理學確診為噁性胸膜間皮瘤患者17例,臨床分期達到Butchart標準Ⅲ期及以上者,分彆採用培美麯塞聯閤順鉑(10例)與培美麯塞聯閤卡鉑(7例)兩種方案化療,對患者的生存率進行統計,瞭解是否存在差異.結果 培美麯塞聯閤順鉑組患者,早期生存率(1～3箇月)略高于培美麯塞聯閤卡鉑組患者,但其差異併無統計學意義(x2值分彆為0、1.52、1.52,P均＞0.05).中期(4～9箇月)生存率培美麯塞聯閤順鉑組高于培美麯塞聯閤卡鉑組,差異有統計學意義(x2值分彆為5.21、4.41、4.41、4.50、4.50、4.55,P均＜0.05).中遠期生存率(10～ 12箇月),培美麯塞聯閤順鉑組與培美麯塞聯閤卡鉑組生存麯線趨嚮一緻,差異併無統計學意義(x2值分彆為1.31、0.09、0.09,P均＞0.05).結論 為增加中期生存率,應儘力採用培美麯塞聯閤順鉑方案.對于部分副反應較大,採用維生素B12及葉痠等輔助藥物能夠緩解的患者亦應選擇此方案.但對于採用瞭上述方式後仍不能降低副作用者選擇培美麯塞聯閤卡鉑的方法也是適噹的,尤其是身體虛弱者.
목적 탐토악성흉막간피류량충내과보수치료방안배미곡새연합순박여배미곡새연합잡박적치료생존솔시부존재차이.방법 아원2005 - 2009년경병이학학진위악성흉막간피류환자17례,림상분기체도Butchart표준Ⅲ기급이상자,분별채용배미곡새연합순박(10례)여배미곡새연합잡박(7례)량충방안화료,대환자적생존솔진행통계,료해시부존재차이.결과 배미곡새연합순박조환자,조기생존솔(1～3개월)략고우배미곡새연합잡박조환자,단기차이병무통계학의의(x2치분별위0、1.52、1.52,P균＞0.05).중기(4～9개월)생존솔배미곡새연합순박조고우배미곡새연합잡박조,차이유통계학의의(x2치분별위5.21、4.41、4.41、4.50、4.50、4.55,P균＜0.05).중원기생존솔(10～ 12개월),배미곡새연합순박조여배미곡새연합잡박조생존곡선추향일치,차이병무통계학의의(x2치분별위1.31、0.09、0.09,P균＞0.05).결론 위증가중기생존솔,응진력채용배미곡새연합순박방안.대우부분부반응교대,채용유생소B12급협산등보조약물능구완해적환자역응선택차방안.단대우채용료상술방식후잉불능강저부작용자선택배미곡새연합잡박적방법야시괄당적,우기시신체허약자.
Objective To compare the survival rates from two conservative strategies in the treatment of malignant pleural mesothelioma (pemetrexed plus cisplatin or pemetrexed plus carboplatin ).Methods Seventeen cases diagnosed of malignant pleural mesothelioma at clinical stages of or over Butchart Ⅲ in our hospital during 2005 -2009 were treated with pemetrexed plus cisplatin (10 cases,Group A)or pemetrexed plus carboplatin (7 cases,Group B ).The difference in the survival rates between these two groups was compared.Results The early survival rate (0 -3 months)in pemetrexed plus cisplatin (group A)-treated group was more than that of pemetrexed plus carboplatin group (group B),but the difference was not statistically significant (x2 =0,1.52,1.52,respectively,P ＞ 0.05 ).For the medium-term survival rate (4 - 9 months),group A was better than group B,and the difference was statistically significant( x2 =5.21,4.41,4.41,4.50,4.50,4.55,respectively,P ＜ 0.05 ).The two groups produced comparable long-term survival rate s (10 -12months) ( x2 =1.31,0.09,0.09,respectively,P ＞ 0.05 ).Conclusion To increase the medium-term survival rate (4 -9 months)of patients with MPM,we prefer to using pemetrexed plus cisplatin regime.For the patients with more severe side effects which can be relieved by folic acid and VitB12,this regime is also recommended.Otherwise,for the patients with unrelievable side effects,especially for those with poor physical condition or a short survival expectation,pemetrexed plus carboplatin is suggested.
